2 January 2014
Smiths Medical has gained a key US Food and Drug Administration (FDA) approval for a customisable infusion system that helps maintain effective epidural analgesia during labour and delivery or with post-operative pain management.
The FDA 510(k) clearance allows Smiths Medical to market its CADD®-Solis pain management system version 3.0 with Programmed Intermittent Bolus (PIB) and Patient Controlled Analgesics (PCA) delivery in the United States.
PIB medication delivery, using the CADD®-Solis v3.0, consistently administers programmed intermittent boluses (doses) that can be supplemented by the patient, improving pain relief and reducing the need for clinical interventions.
The CADD®-Solis ambulatory infusion system, designed for nurses, anesthesiologists, pharmacists and other hospital personnel, is a state-of-the-art system that meets industry recognised standards for advanced error-reduction features in PCA pumps.
General media enquiries
Contact our global media and communications team at:
Please note – the press team can only answer enquiries from accredited members of the press.
Related articles
Smiths announces key geothermal win in its John Crane business
Read our latest company news as John Crane marks a significant geothermal win helping accelerate the delivery of clean, reliable power in the United States
Find out more
Smiths celebrates 175 years of engineering excellence
Read our latest company news as Smiths celebrates its 175th anniversary in 2026.
Find out more
Smiths Group’s John Crane business announces key H1 2026 customer wins
Read the latest news from Smiths, as John Crane announces key H1 2026 customer wins
Find out more